A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. (2018)

First Author: Woodcock VK
Attributed to:  Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2017.484

PubMed Identifier: 29438361

Publication URI: http://europepmc.org/abstract/MED/29438361

Type: Journal Article/Review

Volume: 118

Parent Publication: British journal of cancer

Issue: 6

ISSN: 0007-0920